Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AvidinOX and 177Lu-ST2210 in Solid Tumors
NCT03188328Phase 1Terminated
- Sponsor
- Alfasigma
- Start
- Aug 2017
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Radionuclide Conjugates, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AvidinOX and lutetium-177 ST2210 in solid tumor and lymphoma, sponsored by Alfasigma. Primary endpoints: Maximum Tolerated Dose, Safety and Tolerability and 2 more. Started Aug 2017; status: terminated.
02
Drugs
AvidinOXlutetium-177 ST2210
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03188328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188328.